You need insulin to live. Insulin makes you gain weight.
For the 1.2 million Americans living with type 1 diabetes, survival has long come at a cost — insulin keeps them alive but quietly drives weight gain, which in turn deepens the very complications they are trying to escape. In New Orleans this June, researchers presented early evidence that a once-daily injection called acmopatide may begin to break that cycle, mimicking two natural hormones to improve blood sugar control, reduce body weight, and lower insulin dependence simultaneously. The findings are preliminary, drawn from a small 16-week trial, but they point toward something that has eluded this patient population for decades: a therapy designed not to replace insulin, but to lessen the burden it imposes.
- Decades of insulin-only treatment have trapped type 1 diabetes patients in a cycle where the medicine they need to survive also promotes the weight gain that worsens their disease.
- Nearly two-thirds of the 1.2 million Americans with type 1 diabetes are overweight or obese, creating urgent demand for therapies that go beyond glucose control alone.
- In a 111-person phase 2 trial, acmopatide delivered on multiple fronts at once — cutting A1C by 0.34%, reducing body weight by up to 7%, and lowering insulin requirements by roughly 15%.
- More than half of patients on the mid-range dose reached the A1C target doctors aim for, with no serious safety concerns — a meaningful signal in a field where options have remained narrow.
- Larger and longer trials are still required, but if acmopatide clears those hurdles, it would become the first therapy of its kind purpose-built for type 1 diabetes rather than adapted from type 2 research.
On a June afternoon in New Orleans, researchers presented trial results that could quietly rewrite the treatment story for type 1 diabetes — a condition that has offered patients little beyond insulin for most of its history. The drug, acmopatide, is a once-daily injection that does not replace insulin but instead mimics two natural hormones, GLP-1 and GIP, which regulate blood sugar after meals and signal fullness to the brain. In type 2 diabetes, drugs targeting these same pathways have become some of the most prescribed medicines in the world. Whether they could help in type 1 — where the immune system has destroyed insulin-producing cells entirely — was a genuinely open question.
The trial enrolled 111 adults with type 1 diabetes who were overweight or obese, assigning them to one of three doses of acmopatide or a placebo for 16 weeks. The results, presented at the American Diabetes Association's annual scientific meeting, showed meaningful movement across every measure the researchers tracked. Patients on the middle dose saw A1C fall by 0.34 percentage points from a baseline of 7.5%, with more than half reaching the target of below 7%. They lost up to 7% of body weight and needed roughly 15% less insulin than those on placebo. Tolerability was good, with no serious safety concerns.
The significance lies in what the drug addresses together. Insulin therapy is essential for survival in type 1 diabetes, but it promotes fat storage — and nearly two-thirds of the 1.2 million Americans with the condition are already overweight or obese. That weight, in turn, accelerates heart disease, kidney damage, and other complications. For decades, there has been no clean way out of this trap. Acmopatide, if it advances through larger and longer trials and eventually reaches patients, would be the first therapy purpose-built for type 1 diabetes to address both sides of that problem at once — not borrowed from another disease, but designed for this one.
In New Orleans on a June afternoon, researchers presented results from a trial that could reshape how doctors treat type 1 diabetes—a condition that has long offered patients few choices beyond insulin injections. The drug in question, acmopatide, is a once-daily injection that works differently from insulin. Instead of replacing the hormone the body can no longer make, it mimics two natural hormones that regulate blood sugar and appetite, potentially offering something insulin cannot: weight loss and reduced insulin dependence.
The numbers behind type 1 diabetes paint a particular kind of problem. About 1.2 million Americans live with the condition, and nearly two-thirds of them are overweight or obese. This matters because insulin therapy, while essential for survival, has a side effect that complicates their lives: it promotes fat storage. Over time, the weight gain that follows can trigger heart disease, kidney damage, and other serious complications. For decades, doctors have had no good answer to this trap. You need insulin to live. Insulin makes you gain weight. Weight gain makes your disease harder to manage. The search for a way out of this cycle has been urgent but largely unsuccessful.
The trial enrolled 111 adults with type 1 diabetes who were overweight or obese. They were randomly assigned to receive acmopatide at three different doses or a placebo. The researchers tracked their blood sugar control using A1C, a measure of average glucose over two to three months. They also watched weight, insulin requirements, and real-time glucose readings from wearable monitors.
The results, presented at the American Diabetes Association's annual scientific meeting, showed what the researchers had hoped to find. Patients who received the 4.1-milligram dose—the middle strength tested—saw their A1C drop by 0.34 percentage points from a baseline of 7.5%. More than half of them achieved an A1C below 7%, which is the target doctors aim for. They lost weight too: up to 7% of body weight, depending on the dose. And they needed less insulin—about 15% less than those on placebo. The drug was well tolerated, with no serious safety concerns reported.
Dr. Klara Klein, who led the study, framed the finding as a potential turning point. For people living with type 1 diabetes, she said, the options have remained narrow despite advances in other areas of diabetes care. This drug, if it moves forward through further testing and eventually gains approval, would be the first therapy of its kind designed specifically for type 1 diabetes—not borrowed from type 2 diabetes research, but built from the ground up for a different disease.
What makes acmopatide different is how it works. The two hormones it mimics, GLP-1 and GIP, help the body regulate blood sugar after meals and signal fullness to the brain. In type 2 diabetes, drugs that activate these same pathways have become blockbusters. But type 1 diabetes is fundamentally different: the immune system has destroyed the cells that make insulin, so the body cannot produce it at all. Whether these hormones could help in that context was an open question. This trial suggests they can.
The study was small—111 people is not a large sample—and it lasted only 16 weeks. Larger, longer trials will be needed to confirm these results and watch for any problems that might emerge over time. But the early signal is clear: a drug that improves blood sugar control while reducing both weight and insulin use could address a real gap in how type 1 diabetes is treated. If the drug advances through the regulatory process and reaches patients, it would offer something that has been missing: a way to manage the disease without accepting weight gain as the price of survival.
Notable Quotes
Despite significant advances in diabetes care, people living with type 1 diabetes continue to have limited treatment options beyond insulin. These findings highlight the potential for the first incretin therapy developed specifically for type 1 diabetes to expand treatment options.— Dr. Klara Klein, lead researcher
The Hearth Conversation Another angle on the story
Why does insulin cause weight gain in the first place? That seems like a design flaw.
Insulin's job is to push glucose into cells so they can use it for energy. But it also signals the body to store excess energy as fat. In type 1 diabetes, patients need insulin to survive, but they're often injecting more than a healthy pancreas would naturally release. The excess insulin keeps telling the body to store fat.
So this new drug doesn't replace insulin—it works alongside it?
Exactly. Acmopatide doesn't do insulin's job. It mimics two hormones that help regulate appetite and blood sugar after meals. The idea is that by activating those pathways, you can lower blood sugar and reduce hunger without needing as much insulin.
But type 1 diabetes is an autoimmune disease. Type 2 is metabolic. Why would a drug designed for type 2 work in type 1?
That's the question researchers have been asking. The hormones GLP-1 and GIP work on the same mechanisms in both diseases—they help regulate glucose and appetite. The difference is that type 1 patients still need some insulin because their pancreas is destroyed. But if you can reduce how much insulin they need while improving control, you solve the weight problem.
The trial showed a 0.34% drop in A1C. Is that clinically meaningful?
It depends on where you start. These patients began at 7.5%, which is already close to target. A 0.34% drop brought more than half of them below 7%, which is the goal. It's not a dramatic shift, but combined with weight loss and less insulin, it's meaningful for daily life.
What happens next?
This was phase 2—proof of concept in a small group. The next step is a larger, longer phase 3 trial to confirm safety and efficacy. If that works, the company can seek FDA approval. We're probably years away from patients actually getting this drug.
And if it works, what changes?
For the first time, type 1 diabetes patients would have a non-insulin option that actually helps them lose weight instead of gaining it. That could prevent or delay the heart and kidney complications that come from the weight gain cycle.